Insiders sold over $3M in Insmed stock amid earnings miss and market concerns.

On January 6–8, 2026, multiple Insmed executives, including CEO William Lewis, CFO Sara Bonstein, and COO Roger Adsett, sold a combined total of over 21,000 shares in separate transactions, generating more than $3 million in proceeds. The sales, disclosed in SEC Form 4 filings, occurred at prices between $173.33 and $175.07 per share, with the company’s stock trading down to $170.27 on January 9 amid elevated volume. The insider activity follows a mixed Q3 earnings report showing a $1.75 per share loss, below estimates, though revenue rose 52.4% year-over-year. A Pomerantz LLP investigation into potential investor claims and a large block sale by another insider have added market uncertainty. Despite a "Moderate Buy" analyst consensus and a $205.64 target price, investor concern persists over the sustained insider selling.